Show simple item record

A pilot study of nadolol for overt aggression in developmentally delayed individuals

dc.contributor.authorConnor, Daniel F.
dc.contributor.authorOzbayrak, Kaan R.
dc.contributor.authorBenjamin, Sheldon
dc.contributor.authorMa, Yunsheng
dc.contributor.authorFletcher, Kenneth E.
dc.date2022-08-11T08:10:21.000
dc.date.accessioned2022-08-23T17:05:15Z
dc.date.available2022-08-23T17:05:15Z
dc.date.issued1997-06-01
dc.date.submitted2008-01-15
dc.identifier.citationJ Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):826-34.
dc.identifier.issn0890-8567 (Print)
dc.identifier.pmid9183139
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44817
dc.description.abstractOBJECTIVE: The aim of this preliminary pilot study was to investigate the safety and efficacy of open-label nadolol as an adjunctive pharmacological treatment for aggression and/or inattention/overactivity in a developmentally delayed child, adolescent, and young adult population. METHOD: Twelve subjects enrolled and completed (mean age 13.8 years, range 9 through 24) a 5-month, open, prospective protocol of nadolol (mean dose 109 mg, range 30 through 220 mg) with systematic baseline and outcome evaluations and weekly clinical assessment. RESULTS: All subjects were developmentally delayed and most were cognitively delayed. Ten subjects (83%) showed clinical improvement while receiving nadolol. Significant improvements were noted on observer-rated overt categorical aggression, severity of illness, and global impressions of improvement. No significant effects were found for inattention/overactivity. Nadolol was well tolerated, with few side effects. CONCLUSIONS: Overt categorical aggression presenting in developmentally delayed children, adolescents, and young adults may respond to nadolol treatment.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9183139&dopt=Abstract ">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1097/00004583-199706000-00021
dc.subjectAdolescent
dc.subjectAdrenergic beta-Antagonists
dc.subjectAdult
dc.subjectAggression
dc.subjectChild
dc.subjectDevelopmental Disabilities
dc.subjectHumans
dc.subjectMale
dc.subjectNadolol
dc.subjectPilot Projects
dc.subjectProspective Studies
dc.subjectTreatment Outcome
dc.subjectBehavioral Disciplines and Activities
dc.subjectBehavior and Behavior Mechanisms
dc.subjectCommunity Health and Preventive Medicine
dc.subjectPreventive Medicine
dc.titleA pilot study of nadolol for overt aggression in developmentally delayed individuals
dc.typeJournal Article
dc.source.journaltitleJournal of the American Academy of Child and Adolescent Psychiatry
dc.source.volume36
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/prevbeh_pp/24
dc.identifier.contextkey413360
html.description.abstract<p>OBJECTIVE: The aim of this preliminary pilot study was to investigate the safety and efficacy of open-label nadolol as an adjunctive pharmacological treatment for aggression and/or inattention/overactivity in a developmentally delayed child, adolescent, and young adult population.</p> <p>METHOD: Twelve subjects enrolled and completed (mean age 13.8 years, range 9 through 24) a 5-month, open, prospective protocol of nadolol (mean dose 109 mg, range 30 through 220 mg) with systematic baseline and outcome evaluations and weekly clinical assessment.</p> <p>RESULTS: All subjects were developmentally delayed and most were cognitively delayed. Ten subjects (83%) showed clinical improvement while receiving nadolol. Significant improvements were noted on observer-rated overt categorical aggression, severity of illness, and global impressions of improvement. No significant effects were found for inattention/overactivity. Nadolol was well tolerated, with few side effects.</p> <p>CONCLUSIONS: Overt categorical aggression presenting in developmentally delayed children, adolescents, and young adults may respond to nadolol treatment.</p>
dc.identifier.submissionpathprevbeh_pp/24
dc.contributor.departmentDepartment of Psychiatry
dc.contributor.departmentDepartment of Medicine, Division of Preventive and Behavioral Medicine
dc.source.pages826-34


This item appears in the following Collection(s)

Show simple item record